Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-18-150862
Filing Date
2018-05-03
Accepted
2018-05-03 16:32:03
Documents
3
Period of Report
2018-05-03

Document Format Files

Seq Description Document Type Size
1 6-K d582705d6k.htm 6-K 11470
2 EX-99.1 d582705dex991.htm EX-99.1 8722
3 GRAPHIC g582705g0502233919950.jpg GRAPHIC 3160
  Complete submission text file 0001193125-18-150862.txt   25827
Mailing Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB
Business Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB 44-123-544-3939
Summit Therapeutics plc (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0114
Type: 6-K | Act: 34 | File No.: 001-36866 | Film No.: 18804314
SIC: 2834 Pharmaceutical Preparations